Dose-escalation study of rivaroxaban (BAY 59-7939) – an oral, direct Factor Xa inhibitor – for the prevention of venous thromboembolism in patients undergoing total hip replacement
- 31 December 2007
- journal article
- research article
- Published by Elsevier in Thrombosis Research
- Vol. 120 (5) , 685-693
- https://doi.org/10.1016/j.thromres.2006.12.025
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjectsEuropean Journal of Clinical Pharmacology, 2005
- Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitorClinical Pharmacology & Therapeutics, 2005
- New anticoagulantsJournal of Thrombosis and Haemostasis, 2005
- In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939—an oral, direct Factor Xa inhibitorJournal of Thrombosis and Haemostasis, 2005
- Prevention of Venous ThromboembolismChest, 2004
- Current Options in the Prevention of Thromboembolic DiseaseDrugs, 2004
- Orthopaedic Surgery as a Model for Drug Development in ThrombosisDrugs, 2004
- The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS studyJournal of Thrombosis and Haemostasis, 2003
- Coagulation Factor Xa Inhibition: Biological Background and RationaleCurrent Topics in Medicinal Chemistry, 2001
- Roentgen Diagnosis of Venous Thrombosis in the LegArchives of Surgery, 1972